Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Impact factor and its role in academic promotion

Authors Richard Russell, Dave Singh

Published 16 July 2009 Volume 2009:4 Pages 265—266


Richard Russell,1 Dave Singh2

1Wrexham Park Hospital, Berkshire, UK; 2Northwest Lung Research Centre, South Manchester University Hospitals Trust, Manchester, UK

This statement was adopted unanimously at the May 17, 2009 meeting of the International Respiratory Journal Editors Roundtable.

In our collective experience as editors of international peer-reviewed journals, we propose that the impact factor calculated for individual journals should not be used as a basis for evaluating the significance of an individual scientist’s past performance or scientific potential. There are several reasons not to equate the impact factor of a journal in which the scientist publishes with the quality of the scientist’s research.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

ICS and COPD: Time to clear the air

Paul A Ford, Richard EK Russell, Peter J Barnes

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:289-290

Published Date: 31 July 2009

Readers of this article also read:

Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia

Riva S, Nobili A, Djade CD, Mancuso ME, Santagostino E, Pravettoni G

Clinical Interventions in Aging 2015, 10:1141-1146

Published Date: 9 July 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A

George LA, Camire RM

Journal of Blood Medicine 2015, 6:131-141

Published Date: 24 April 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson, Sisse R Ostrowski

Drug Design, Development and Therapy 2010, 4:107-116

Published Date: 29 June 2010

Does plasmin have anticoagulant activity?

Jane Hoover-Plow

Vascular Health and Risk Management 2010, 6:199-205

Published Date: 26 March 2010